Lorundrostat hydrobromide is under clinical development by Mineralys Therapeutics and currently in Phase III for Resistant Hypertension. According to GlobalData, Phase III drugs for Resistant Hypertension does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Lorundrostat hydrobromide LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lorundrostat hydrobromide overview

Lorundrostat hydrobromide is under development for the treatment of uncontrolled hypertension, resistant hypertension and chronic kidney disease. It is administered orally. The drug candidate act by targeting aldosterone synthase (CYP11B2).

Mineralys Therapeutics overview

Mineralys Therapeutics. (Mineralys Therapeutics) is a private, clinical-stage biopharmaceutical company that develops novel therapy for the treatment of hypertension. Mineralys Therapeutics is headquartered in Radnor, Pennsylvania, the US.

For a complete picture of Lorundrostat hydrobromide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.